Search PubMed⌕ Search

Biomedical subjects

T A Ban

Publications and source records attributed to T A Ban.

At least 163 records · Page 9Linked to original sources
PubMed1975

Psychotherapeutic profile of a new psychoactive drug trazodone (AF-1161).

In a systematic clinical study, including four uncontrolled clinical trials with psychiatric patients belonging to four different diagnostic groups, trazodone, the first triazolopyridine compound subjected to clinical investigation, was found to be a therapeutically effective psychoactive drug. Since the most consistent therapeutic action of trazodone was seen to be in the depressive syndrome, i.e., Guilt Feelings, Motor Retardation and Depressive Mood, it was suggested that trazodone has a therapeutic effect on depressive symptoms whether they occur in depression, neurosis, organic brain syndrome or schizophrenia.

Adult↗
PubMed1975

Clomacran in the treatment of schizophrenic patients: a comparison of two assessment methods.

In an uncontrolled clinical trial clomacran, the chlorpromazine analogue of the acridane series, was found to be therapeutically effective in the treatment of newly admitted schizophrenic patients. There was essentially no difference in the sensitivity of the two assessment instruments, i.e. BPRS and PAF, in the detection of therapeutic changes. On the other hand, the PAF, a 123-item scale, was found to be more sensitive for the description of a schizophrenic patient population than the BPRS, an 18-item scale.

Acridines↗
PubMed1975

A clinical trial with nomifensin, a new antidepressant drug.

An uncontrolled clinical trial with 10 depressed patients was conducted to identify the psychopathological symptoms which may be affected by nomifensin administration, and to reveal the possible adverse effects of the drug. Consistent statistically significant improvement was noted in the course of the clinical trial on all of the assessment instruments used, and - with the exception of one patient - all improved while receiving nomifensin. Most of the therapeutic changes were seen within the first three weeks of treatment, and they included improvements of depression, as well as of hostility, a symptom which usually remains unaffeCTED BY TRICYclic antidepressant drugs. To verify the favorable therapeutic effects of nomifensin in depressed psychiatric patients, a standard-controlled clinical trial is in progress; and to verify the action mechanism of nomifensin, a study employing the probenecid technique and the measurement of spinal homovanillic acid (HVA) and 5-hydroxyindole acetic acid (5hiaa) concentration is planned.

Adjustment Disorders↗